Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women
임산부와 수유부에서 코로나19 mRNA 백신의 면역원성
Article
[키워드] antibody
Antibody Response
Antibody titers
assays
B.1.1.7
B.1.351
B.1.351 variant
B.1.351 variants
binding
binding and neutralizing antibodies
binding domain
Blood
BNT162b2
breast milk
CD4
CD8 T-cell response
CD8 T-cell responses
Cellular immune response
Cord blood
COVID-19
COVID-19 vaccine
COVID-19 vaccine trials
COVID-19 vaccines
cross-reactive antibody
enrolled
enzyme
enzyme-linked immunospot
evaluate
evaluated
excluded
exploratory
Exploratory analysis
Fever
Follow-up
functional
Humoral and cellular immune responses
IFN-γ
immune responses
immunogenic
immunogenicity
ImmunoSpot
increased risk
lactating
lactating women
Messenger RNA
Moderna
morbidity
morbidity and mortality
mRNA
mRNA vaccine
mRNA-1273
Neutralizing
Neutralizing antibodies
neutralizing antibody
Neutralizing antibody titer
neutralizing antibody titers
nonpregnant
outcome
Pfizer-BioNTech
Phase 3
Population
pregnant
pregnant women
preserved
prospective cohort study
receipt
reduced
reported
response
SARS-CoV-2 B.1.1.7
SARS-COV-2 infection
SARS-CoV-2 receptor
SARS-CoV-2 USA-WA1/2020
SARS-CoV-2 variant
SARS-CoV-2 variants
Spike-specific T-cell responses
T-cell Response
T-cell responses
the SARS-CoV-2
transported
vaccination
Vaccine
vaccine dose
Viral
Viral variants
were assessed
white
women
[DOI] 10.1001/jama.2021.7563 PMC 바로가기 [Article Type] Article
[DOI] 10.1001/jama.2021.7563 PMC 바로가기 [Article Type] Article